Results 211 to 220 of about 35,890 (293)

Pathological Complete Response in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Following Conversion Therapy With TACE, HAIC, Lenvatinib, and Sintilimab: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) is an advanced disease with poor prognosis and limited treatment options. Conversion therapy integrating locoregional and systemic modalities may expand surgical eligibility, but achieving pathological complete response (pCR) remains rare.
Weidong Zhang   +5 more
wiley   +1 more source

Ultra‐Micro Powder From Edible Plants (Pueraria lobata, Cornus officinalis, Cistanche deserticola, and Dendrobium officinale) Reshapes Intestinal Flora and Attenuates Liver Injury in Alcohol‐Induced Mice

open access: yesFood Science &Nutrition, Volume 14, Issue 5, May 2026.
Ultra‐micro powder from edible plants (Pueraria lobata, Cornus officinalis, Cistanche deserticola, and Dendrobium officinale) attenuates alcoholic liver injury by regulating the gut‐liver axis. It primarily reshapes the intestinal microbiota by restoring beneficial Lactobacillus populations and suppressing pathogenic bacteria like Proteobacteria and ...
Jia‐Yu Huang   +5 more
wiley   +1 more source

Peripheral Blood Biomarkers Predict Outcomes in Advanced Cancers Treated With Anti‐PD‐1 Therapy

open access: yesImmunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
This study identifies dNLR≤ 3.18, AMC ≤ 0.48, IL‐6 ≤ 12.35, and squamous histology as independent predictors of improved survival in advanced cancers treated with anti‐PD‐1 therapy. A novel biomarker‐based model demonstrates high accuracy for 1‐year survival stratification, aiding clinical decision‐making.
Chunxia Feng   +4 more
wiley   +1 more source

Personal experience with orthotopic liver transplantation. [PDF]

open access: yes, 1972
Corman, J   +7 more
core  

From DNA Methylation Microarray to Digital PCR: A Stepwise Strategy for Tissue Specific cfDNA Biomarker Development

open access: yesJournal of Clinical Laboratory Analysis, Volume 40, Issue 9, May 2026.
Overview of a DNA methylation biomarker development pipeline, from discovery and assay design to screening, performance evaluation, and specificity testing in clinical sample matrices. ABSTRACT Background Tissue‐specific cell‐free DNA (cfDNA) offers promise as a minimally invasive biomarker of organ injury.
David H. Murray   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy